Search Results for: covid-19
Articles
CONTAINER PLATFORMS - Ready-to-Use Containers: Real Benefits, Important Challenges & Evolving Value June 3, 2024
Gregor Deutschle and Gabriele Maier examine key benefits, dynamics driving the adoption of RTU container platforms, and several important areas of continuing evolution in the RTU market.
BioNTech & CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem May 29, 2024
BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) are expanding their strategic partnership to contribute to building a sustainable...IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study May 13, 2024
IMUNON, Inc. recently announced DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for...EXECUTIVE INTERVIEW - Cocrystal Pharma: Utilizing Structure-Based Technologies to Provide First- & Best-In-Class Antiviral Drugs to Address Critically Unmet Medical Needs April 29, 2024
Dr. Sam Lee, Cocrystal Pharma’s President and co-CEO, discusses the company’s latest achievements in antiviral drug development.
Oligonucleotides & mRNA Vaccines Dominate in Strategic Alliances for RNA Therapies in Major APAC Countries April 26, 2024
RNA-based therapies have already proven and will continue to play an integral role in the development of novel therapeutic agents...CanSinoBIO CSO Shares Latest Results of Innovative Pneumococcal Vaccine April 26, 2024
On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the...Naobios & Sumagen Sign Exclusive Partnership to Develop HIV Vaccine April 15, 2024
Naobios will manage process development and initiate launch of cGMP manufacturing for Phase 2 clinical trials….
SPECIAL FEATURE - Excipients: Advanced Biologics Require Innovative Excipient Science March 29, 2024
Contributor Cindy H. Dubin speaks with several leading companies to discuss novel and functional excipients being developed, the role they will play in reformulations and new formulations, and their versatility in drug delivery.
VACCINE DEVELOPMENT - Therapeutic Vaccines Development: At the Edge of a New Revolution March 28, 2024
Mario Davinelli, PhD, Narcisa Mesaros, MD, David Morland, and Judith Neville, PhD, say therapeutic vaccines are an exciting area of research that has the potential to revolutionize the way we treat diseases.
Revive Therapeutics to Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID March 19, 2024
Revive Therapeutics Ltd. recently announced the FDA advised the company to submit a Type C meeting request to discuss evaluating...Noramco Announces Strategic Alignment With Purisys & Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API & Drug Product Supply Chain Services Provider March 14, 2024
Noramco recently announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired….
DRUG DEVELOPMENT EXECUTIVE - Thermo Fisher Scientific: What to Expect From the Next Wave of RNA-Based Therapeutics February 29, 2024
Dr. Dale Patterson, Vice President and General Manager, Molecular Biology at Thermo Fisher Scientific, delves into the world of RNA therapies and understand their next act beyond COVID-19.
VACCINE DEVELOPMENT - A Healthier Global Population Through a Universal Influenza & Multi-Virus Vaccine February 28, 2024
Jeff Fischer, MBA, says we need to have an eye toward universal influenza or multi-virus vaccines that have the ability to provide broad coverage as viral strains continue to evolve.
ENGINEERING BIOLOGY - Scaling Engineering Biology to Accelerate Advances in Healthcare February 28, 2024
Raquel Sanches-Kuiper and Matthew Hayes, PhD, say the development of a benchtop synthesis platform has the potential to expedite the discovery and development time for drugs and biotherapeutics, greatly accelerating the rate at which engineering biology can shape the future of healthcare.
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics & Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform February 28, 2024
Dyadic International, Inc. recently announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration...Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer February 27, 2024
IMUNON, Inc. recently announced Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a...Dyadic Advances Collaboration With Israel Institute for Biological Research Targeting Bio-Threats & Emerging Disease Solutions February 21, 2024
Dyadic International, Inc. and Israel Institute for Biological Research (IIBR) recently announced it has advanced its collaboration with IIBR and...Evonik Partners With University of Mainz to Commercialize New Class of PEG Lipids for Nucleic Acid Delivery February 20, 2024
Evonik and the University of Mainz have signed a license agreement to commercialize randomized polyethylene glycols (rPEGs), a new class of PEGs. Evonik intends to use….
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published February 15, 2024
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys…..
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress February 6, 2024
MiNK Therapeutics, Inc. recently announced the publication of results in Nature Communications from a Phase 1/2 study of agenT-797 in...
